Loading...

Ajay Maker, MD

Title(s)Professor, Surgery
SchoolSchool of Medicine
Address550 16th Street
San Francisco CA 94158
Phone--
vCardDownload vCard

    Collapse Biography 
    Collapse Education and Training
    Brown University, Providence, RIBachelor of Arts
    Yale University School of Medicine, New Haven, CTM.D.
    Brigham and Women's Hospital/Harvard Medical School, Boston, MAGeneral Surgery
    National Institutes of Health (NIH)/National Cancer Institute (NCI), Bethesda, MDPost-doctorateTumor Immunology
    Memorial Sloan-Kettering Cancer Center, New York, NYSurgical Oncology Fellowship
    National Institutes of Health (NIH)/National Cancer Institute (NCI), Surgery Branch, Bethesda, MDSurgical Oncology Fellowship

    Collapse Overview 
    Collapse Overview
    Biography:

    Dr. Ajay V. Maker M.D. is a surgical oncologist and chief of the UCSF Division of Surgical Oncology. He is an expert in surgically treating complex gastrointestinal and hepatopancreatobiliary diseases (those affecting the liver, pancreas, gallbladder and bile ducts), as well as melanomas and sarcomas.

    Maker's research aims to improve early detection of pancreas cancer and to develop new therapies for treating metastases (cancers that have spread from a primary site in the body). Under grants awarded by the Department of Defense and National Institutes of Health (NIH), he works on designing novel immunotherapies (treatments that harness the immune system to fight tumors), particularly for liver metastases from colon cancer. He is one of only a few surgeons to receive the NIH MERIT award and U.S. Army Medical Research Acquisition Activity Cancer Impact Award.

    Maker earned his medical degree at Yale School of Medicine. He completed a residency in general surgery at Brigham and Women's Hospital, an affiliate of Harvard Medical School. He trained in surgical oncology at the NIH and completed postdoctoral studies in tumor immunology at the National Cancer Institute; this research included working in trials that led to the Food and Drug Administration approval of Ipilimumab as a new treatment for metastatic melanoma. He later completed a fellowship in surgical oncology at Memorial Sloan Kettering Cancer Center and then gained experience in minimally invasive surgical techniques at the University of Paris. He came to UCSF from his hometown of Chicago, where he was a tenured professor of surgery and of microbiology and immunology at the University of Illinois at Chicago.

    In 2015, Maker was the European Society of Surgical Oncology's international traveling fellow and was later honored with the Society of Surgical Oncology's Clinical Investigator Award. He has published more than 170 manuscripts, abstracts and book chapters, and he lectures all over the world. He serves on the editorial boards of many surgical and scientific journals; serves on NIH study sections, which evaluate the merit of proposed research; and has held leadership positions in numerous academic and scientific societies, including program chair of the Americas Hepato-Pancreato-Biliary Association and chair of the Society of Surgical Oncology's gastrointestinal working group. He is also active in various medical societies, including the Surgical Biology Club , Western Surgical Association, American Society of Clinical Oncology and Pancreas Club. He has been named numerous times to Castle Connolly's Top Doctors and Top Doctors for Cancer lists. He is a fellow of the American College of Surgeons and Society of Surgical Oncology.

    Research Interests and Funding:

    Dr. Maker graduated from Brown University with honors in fine arts and biology, completing his honors thesis in the NASA-funded lab of Dr. Herman Vandenberg in tissue engineering. Thereafter, he enrolled in the Yale School of Medicine and was selected to enter the Basic Science Research Training Fellowship where he was awarded the ADA Medical Scholars Award and the AAS/Novartis Research Award for his work in the R01-funded lab of surgeon Dana Andersen on elucidating mechanisms of pancreatogenic diabetes. He completed his general surgery residency at Harvard University's Brigham and Women's Hospital and a tumor immunology post-doctorate fellowship in the laboratory of Dr. Steven Rosenberg in the Surgery Branch of the NIH/NCI, during which time he was first author on many of the initial phase I/II trials utilizing anti-CTLA4 antibodies. This work was later honored with the "most cited article" award by the Society of Surgical Oncology.

    Dr. Maker went on to complete surgical oncology fellowships at the NCI and Memorial Sloan-Kettering Cancer Center, where he continued translational bench research in the Ludwig Cancer Institute, funded, in part, by an ASCO Merit Award and an NCI EDRU U01. He has focused the efforts of his research career on expanding the role of immunotherapy for gastrointestinal tumors and has aligned his clinical practice to coincide with his research interests. His NCI/NIH and DoD-funded research program has identified an immunostimulatory cytokine capable of activating and supporting the proliferation of antigen-specific T-cells to incite an anti-tumor immune response in colorectal liver metastases. This strategy is currently being investigated in combination with oncolytic viruses and immune checkpoint blockade to elicit complete tumor responses. This work has been funded over time as PI by internal funding, the Warren and Clara Cole Foundation of the ACS, the NIH through both K08 and UL1 mechanisms, the DoD (Cancer Impact Award), R37 MERIT from the NCI, and the Society of Surgical Oncology (Investigator of the Year Award).

    Dr. Maker's lab also investigates novel drug combinations that stimulate immunogenic cell death and that generate anti-tumor immune responses to treat GI tumor liver metastases. As part of these studies, Dr. Maker has developed multiple unique orthotopic animal models in which to study solid organ metastases that have led to multiple federally funded collaborations, including work on the novel Oncopig porcine large animal cancer model for liver and pancreatic cancer.

    Furthermore, Dr. Maker has been a leader in the international IPMN biomarkers research group, and has developed a gene signature to predict malignancy in IPMN from pancreatic cyst fluid. He houses the international IPMN cyst fluid repository, one of the largest biobanks of its kind, for which he serves as the international PI. With this collaborative, he is currently validating a single-platform
    biosignature to accurately predict the malignant potential of pancreatic cysts.

    Finally, as a clinical surgeon with a passion for developing new laparoscopic and robotic techniques in complex surgical oncology, he has also maintained a robust clinical database from which multiple techniques papers and outcomes studies have been generated along with his residents.

    Collapse Research 
    Collapse Research Activities and Funding
    Stimulating Lymphocyte Activation Combined with Inhibition of Immunosuppressive Signals in Colon Cancer Metastases
    NIH R37CA238435Jan 22, 2020 - Dec 31, 2024
    Role: Principal Investigator
    Enhancing anti-tumor immune responses in colon cancer metastases
    NIH K08CA190855Sep 17, 2014 - Aug 31, 2020
    Role: Principal Investigator

    Collapse ORNG Applications 
    Collapse Websites

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help. to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    Altmetrics Details PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Race and Gender Differences in Awareness of Colorectal Cancer Screening Tests and Guidelines Among Recently Diagnosed Colon Cancer Patients in an Urban Setting. J Cancer Educ. 2021 Jun; 36(3):567-575. Carnahan LR, Jones L, Brewer KC, Watts EA, Peterson CE, Ferrans CE, Cipriano-Steffens T, Polite B, Maker AV, Chowdhery R, Molina Y, Rauscher GH. PMID: 31838729.
      View in: PubMed   Mentions:
    2. Is there a difference in utilization of a perioperative treatment approach for gastric cancer between safety net hospitals and tertiary referral centers? J Surg Oncol. 2021 Jun 01. Turgeon MK, Lee RM, Keilson JM, Ju MR, Porembka MR, Alterio RE, Kronenfeld J, Datta J, Goel N, Wang A, Lee AY, Fernandez M, Richter H, Maker AV, Maithel SK, Russell MC. PMID: 34061369.
      View in: PubMed   Mentions:
    3. Combining On-Table Embolization with Immediate Resection to Safely Excise Giant Hepatic Hemangiomas. J Gastrointest Surg. 2021 Feb 25. Maker AV, Al Rameni D, Prabhakar N. PMID: 33634420.
      View in: PubMed   Mentions:    Fields:    
    4. Combination Immunotherapy With LIGHT and Interleukin-2 Increases CD8 Central Memory T-Cells In Vivo. J Surg Res. 2021 Feb 22; 263:44-52. Fernandez MF, Qiao G, Tulla K, Prabhakar BS, Maker AV. PMID: 33631377.
      View in: PubMed   Mentions:    Fields:    
    5. ASO Author Reflections: How Can We Improve the Postoperative Experience for Our Pancreatic Cancer Patients? A Practical Technique to Optimize Pain Control After Major Abdominal Surgery. Ann Surg Oncol. 2021 Apr; 28(4):2296-2298. Maker AV. PMID: 32914388.
      View in: PubMed   Mentions:
    6. Surgeon-Placed Continuous Wound Infusion Pain Catheters Markedly Decrease Narcotic Use and Improve Outcomes After Pancreatic Tumor Resection. Ann Surg Oncol. 2021 Apr; 28(4):2287-2295. Kone LB, Kunda NM, Tran TB, Maker AV. PMID: 32880771.
      View in: PubMed   Mentions:
    7. Epidural Analgesia Is Associated with Prolonged Length of Stay After Open HPB Surgery in Over 27,000 Patients. J Gastrointest Surg. 2020 Jul 28. Kone LB, Maker VK, Banulescu M, Maker AV. PMID: 32725519.
      View in: PubMed   Mentions:
    8. Perioperative Broad-spectrum Antibiotics are Associated With Decreased Surgical Site Infections Compared to 1st-3rd Generation Cephalosporins After Open Pancreaticoduodenectomy in Patients With Jaundice or a Biliary Stent. Ann Surg. 2020 Jul 24. Kone LB, Torres C, Banulescu M, Maker VK, Maker AV. PMID: 32740256.
      View in: PubMed   Mentions:
    9. Should Drains Suck? A Propensity Score Analysis of Closed-Suction Versus Closed-Gravity Drainage After Pancreatectomy. J Gastrointest Surg. 2021 May; 25(5):1224-1232. Kone LB, Maker VK, Banulescu M, Maker AV. PMID: 32394123.
      View in: PubMed   Mentions:
    10. Oncolytic adenovirus encoding LIGHT (TNFSF14) inhibits tumor growth via activating anti-tumor immune responses in 4T1 mouse mammary tumor model in immune competent syngeneic mice. Cancer Gene Ther. 2020 Dec; 27(12):923-933. Dai S, Lv Y, Xu W, Yang Y, Liu C, Dong X, Zhang H, Prabhakar BS, Maker AV, Seth P, Wang H. PMID: 32307442.
      View in: PubMed   Mentions:
    11. Management of Cancer Surgery Cases During the COVID-19 Pandemic: Considerations. Ann Surg Oncol. 2020 Jun; 27(6):1717-1720. Bartlett DL, Howe JR, Chang G, Crago A, Hogg M, Karakousis G, Levine E, Maker A, Mamounas E, McGuire K, Merchant N, Shibata D, Sohn V, Solorzano C, Turaga K, White R, Yang A, Yoon S, Society of Surgical Oncology . PMID: 32270420.
      View in: PubMed   Mentions:
    12. A propensity score analysis of over 12,000 pancreaticojejunal anastomoses after pancreaticoduodenectomy: does technique impact the clinically relevant fistula rate? HPB (Oxford). 2020 10; 22(10):1394-1401. Kone LB, Maker VK, Banulescu M, Maker AV. PMID: 32019740.
      View in: PubMed   Mentions:
    13. MADD silencing enhances anti-tumor activity of TRAIL in anaplastic thyroid cancer. Endocr Relat Cancer. 2019 06 01; 26(6):551-563. Saini S, Sripada L, Tulla K, Qiao G, Kunda N, Maker AV, Prabhakar BS. PMID: 30999276.
      View in: PubMed   Mentions:
    14. Cyst Fluid Biosignature to Predict Intraductal Papillary Mucinous Neoplasms of the Pancreas with High Malignant Potential. J Am Coll Surg. 2019 05; 228(5):721-729. Maker AV, Hu V, Kadkol SS, Hong L, Brugge W, Winter J, Yeo CJ, Hackert T, Büchler M, Lawlor RT, Salvia R, Scarpa A, Bassi C, Green S. PMID: 30794864.
      View in: PubMed   Mentions:
    15. Loss of MADD expression inhibits cellular growth and metastasis in anaplastic thyroid cancer. Cell Death Dis. 2019 02 13; 10(2):145. Saini S, Sripada L, Tulla K, Kumar P, Yue F, Kunda N, Maker AV, Prabhakar BS. PMID: 30760700.
      View in: PubMed   Mentions:
    16. Impact of Immunotherapy after Resection of Pancreatic Cancer. J Am Coll Surg. 2019 07; 229(1):19-27.e1. Tran TB, Maker VK, Maker AV. PMID: 30742911.
      View in: PubMed   Mentions:
    17. Molecular aberrations and signaling cascades implicated in the pathogenesis of anaplastic thyroid cancer. Biochim Biophys Acta Rev Cancer. 2019 12; 1872(2):188262. Saini S, Maker AV, Burman KD, Prabhakar BS. PMID: 30605717.
      View in: PubMed   Mentions:
    18. Management of asymptomatic, well-differentiated PNETs: results of the Delphi consensus process of the Americas Hepato-Pancreato-Biliary Association. HPB (Oxford). 2019 05; 21(5):515-523. Mansour JC, Chavin K, Morris-Stiff G, Warner SG, Cardona K, Fong ZV, Maker A, Libutti SK, Warren R, St Hill C, Celinski S, Newell P, Ly QP, Howe J, Coburn N. PMID: 30527517.
      View in: PubMed   Mentions:
    19. Does attending a Delphi consensus conference impact surgeon attitudes? Survey results from the Americas HepatoPancreatoBiliary Association consensus conference on small asymptomatic pancreatic neuroendocrine tumors. HPB (Oxford). 2019 05; 21(5):524-530. Maker AV, Tran TB, Coburn N, Fong ZV, Cardona K, Newell P, Morris-Stiff G, Chavin K, Mansour J, members of the AHPBA Research Committee Consensus Conference . PMID: 30442562.
      View in: PubMed   Mentions:
    20. Therapeutic advances in anaplastic thyroid cancer: a current perspective. Mol Cancer. 2018 10 23; 17(1):154. Saini S, Tulla K, Maker AV, Burman KD, Prabhakar BS. PMID: 30352606.
      View in: PubMed   Mentions:
    21. ASO Author Reflections: Improving Identification of Intraductal Papillary Mucinous Neoplasm Patients at Risk-Current Status and the Role of IPMN Molecular Biomarkers. Ann Surg Oncol. 2018 12; 25(Suppl 3):818-819. Maker AV. PMID: 30311163.
      View in: PubMed   Mentions:
    22. Identification of a Novel OX40L+ Dendritic Cell Subset That Selectively Expands Regulatory T cells. Sci Rep. 2018 10 08; 8(1):14940. Marinelarena A, Bhattacharya P, Kumar P, Maker AV, Prabhakar BS. PMID: 30297856.
      View in: PubMed   Mentions:
    23. KRASG12D and TP53R167H Cooperate to Induce Pancreatic Ductal Adenocarcinoma in Sus scrofa Pigs. Sci Rep. 2018 08 22; 8(1):12548. Principe DR, Overgaard NH, Park AJ, Diaz AM, Torres C, McKinney R, Dorman MJ, Castellanos K, Schwind R, Dawson DW, Rana A, Maker A, Munshi HG, Rund LA, Grippo PJ, Schook LB. PMID: 30135483.
      View in: PubMed   Mentions:
    24. Vaccination With Mitoxantrone-Treated Primary Colon Cancer Cells Enhances Tumor-Infiltrating Lymphocytes and Clinical Responses in Colorectal Liver Metastases. J Surg Res. 2019 01; 233:57-64. Qin J, Kunda NM, Qiao G, Tulla K, Prabhakar BS, Maker AV. PMID: 30502288.
      View in: PubMed   Mentions:
    25. Critical role of OX40 signaling in the TCR-independent phase of human and murine thymic Treg generation. Cell Mol Immunol. 2019 02; 16(2):138-153. Kumar P, Marinelarena A, Raghunathan D, Ragothaman VK, Saini S, Bhattacharya P, Fan J, Epstein AL, Maker AV, Prabhakar BS. PMID: 29578532.
      View in: PubMed   Mentions: 10     Fields:    Translation:HumansAnimalsCells
    26. What is the Incidence of Malignancy in Resected Intraductal Papillary Mucinous Neoplasms? An Analysis of Over 100 US Institutions in a Single Year. Ann Surg Oncol. 2018 Jun; 25(6):1746-1751. Khoury RE, Kabir C, Maker VK, Banulescu M, Wasserman M, Maker AV. PMID: 29560572.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    27. Do Drains Contribute to Pancreatic Fistulae? Analysis of over 5000 Pancreatectomy Patients. J Gastrointest Surg. 2018 06; 22(6):1007-1015. El Khoury R, Kabir C, Maker VK, Banulescu M, Wasserman M, Maker AV. PMID: 29435899.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    28. Can we better predict the biologic behavior of incidental IPMN? A comprehensive analysis of molecular diagnostics and biomarkers in intraductal papillary mucinous neoplasms of the pancreas. Langenbecks Arch Surg. 2018 Mar; 403(2):151-194. Tulla KA, Maker AV. PMID: 29218397.
      View in: PubMed   Mentions:
    29. Port-Site Resection in the Surgical Management of Incidental Gallbladder Cancer: A Still Inconclusive Question: A Reply. Ann Surg Oncol. 2017 12; 24(Suppl 3):647-648. Maker AV, Jarnagin WR. PMID: 29116487.
      View in: PubMed   Mentions:
    30. Examining racial disparities in colon cancer clinical delay in the Colon Cancer Patterns of Care in Chicago study. Ann Epidemiol. 2017 11; 27(11):731-738.e1. Jones LA, Ferrans CE, Polite BN, Brewer KC, Maker AV, Pauls HA, Rauscher GH. PMID: 29173578.
      View in: PubMed   Mentions:
    31. The Oncopig Cancer Model: An Innovative Large Animal Translational Oncology Platform. Front Oncol. 2017; 7:190. Schachtschneider KM, Schwind RM, Newson J, Kinachtchouk N, Rizko M, Mendoza-Elias N, Grippo P, Principe DR, Park A, Overgaard NH, Jungersen G, Garcia KD, Maker AV, Rund LA, Ozer H, Gaba RC, Schook LB. PMID: 28879168.
      View in: PubMed   Mentions:
    32. PKC-? is dispensable for OX40L-induced TCR-independent Treg proliferation but contributes by enabling IL-2 production from effector T-cells. Sci Rep. 2017 07 26; 7(1):6594. Alharshawi K, Marinelarena A, Kumar P, El-Sayed O, Bhattacharya P, Sun Z, Epstein AL, Maker AV, Prabhakar BS. PMID: 28747670.
      View in: PubMed   Mentions: 3     Fields:    Translation:AnimalsCells
    33. Perioperative management of endocrine insufficiency after total pancreatectomy for neoplasia. Langenbecks Arch Surg. 2017 Sep; 402(6):873-883. Maker AV, Sheikh R, Bhagia V, Diabetes Control and Complications Trial (DCCT) Research Group . PMID: 28733926.
      View in: PubMed   Mentions:
    34. A Technique to Define Extrahepatic Biliary Anatomy Using Robotic Near-Infrared Fluorescent Cholangiography. J Gastrointest Surg. 2017 Nov; 21(11):1961-1962. Maker AV, Kunda N. PMID: 28585107.
      View in: PubMed   Mentions:
    35. Targeting cancer with tumor-specific therapeutic strategies-metabolic reprogramming beyond the Warburg effect. Transl Cancer Res. 2017 May; 6(Suppl 3):S585-S586. Grippo P, Maker AV. PMID: 28868241.
      View in: PubMed   Mentions:
    36. Mitochondrial protein 18 (MTP18) plays a pro-apoptotic role in chemotherapy-induced gastric cancer cell apoptosis. Oncotarget. 2017 Aug 22; 8(34):56582-56597. Aung LHH, Li R, Prabhakar BS, Maker AV, Li P. PMID: 28915614.
      View in: PubMed   Mentions:
    37. Utilization and impact of adjuvant chemotherapy among patients with resected stage II colon cancer: a multi-institutional analysis. J Surg Res. 2017 07; 215:12-20. Ejaz A, Casadaban L, Maker AV. PMID: 28688636.
      View in: PubMed   Mentions:
    38. LIGHT Elevation Enhances Immune Eradication of Colon Cancer Metastases. Cancer Res. 2017 04 15; 77(8):1880-1891. Qiao G, Qin J, Kunda N, Calata JF, Mahmud DL, Gann P, Fu YX, Rosenberg SA, Prabhakar BS, Maker AV. PMID: 28249900.
      View in: PubMed   Mentions:
    39. Isolated Pancreatic Uncinate Duct IPMN. J Gastrointest Surg. 2017 04; 21(4):744-745. Maker AV, Maker VK. PMID: 28205123.
      View in: PubMed   Mentions:
    40. Colon cancer cell treatment with rose bengal generates a protective immune response via immunogenic cell death. Cell Death Dis. 2017 02 02; 8(2):e2584. Qin J, Kunda N, Qiao G, Calata JF, Pardiwala K, Prabhakar BS, Maker AV. PMID: 28151483.
      View in: PubMed   Mentions:
    41. Can Colon Cancer Recurrence and Metastases Be Determined After Surgical Resection Using a Gene Expression Signature? J Clin Oncol. 2017 04 20; 35(12):1372-1373. Casadaban L, Maker AV. PMID: 28113016.
      View in: PubMed   Mentions:
    42. Gene-expression profiling to predict responsiveness to immunotherapy. Cancer Gene Ther. 2017 Mar; 24(3):134-140. Jamieson NB, Maker AV. PMID: 27834354.
      View in: PubMed   Mentions:
    43. Targeting the metabolic pathway of human colon cancer overcomes resistance to TRAIL-induced apoptosis. Cell Death Discov. 2016; 2:16067. Carr RM, Qiao G, Qin J, Jayaraman S, Prabhakar BS, Maker AV. PMID: 27648301.
      View in: PubMed   Mentions:
    44. Adjuvant chemotherapy is associated with improved survival in patients with stage II colon cancer. Cancer. 2016 Nov 15; 122(21):3277-3287. Casadaban L, Rauscher G, Aklilu M, Villenes D, Freels S, Maker AV. PMID: 27417445.
      View in: PubMed   Mentions:
    45. Techniques to perform robotic left adrenalectomy in the obese patient. Surg Endosc. 2017 02; 31(2):950. Maker AV, Maker VK. PMID: 27387175.
      View in: PubMed   Mentions:
    46. Hepatectomy After Yttrium-90 (Y90) Radioembolization-Induced Liver Fibrosis. J Gastrointest Surg. 2016 Apr; 20(4):869-70. Maker AV, August C, Maker VK, Weisenberg E. PMID: 26847353.
      View in: PubMed   Mentions:
    47. A Minimally Invasive Technique to Obtain Optimal Tumor Margins in Anatomically Confined Locations Using a Contoured Stapler. Ann Surg Oncol. 2015 Dec; 22 Suppl 3:S340. Maker AV, Valbuena V, Maker VK. PMID: 26265368.
      View in: PubMed   Mentions:
    48. Precise identification of immunotherapeutic targets for solid malignancies using clues within the tumor microenvironment-Evidence to turn on the LIGHT. Oncoimmunology. 2016; 5(1):e1069937. Maker AV. PMID: 26942091.
      View in: PubMed   Mentions:
    49. The Potential of Intralesional Rose Bengal to Stimulate T-Cell Mediated Anti-Tumor Responses. J Clin Cell Immunol. 2015 Aug; 6(4). Maker AV, Prabhakar B, Pardiwala K. PMID: 26618054.
      View in: PubMed   Mentions:
    50. Techniques to perform a laparoscopic right adrenalectomy for metastases abutting the liver, renal vein, and posterior vena cava. Surg Endosc. 2016 Mar; 30(3):1226. Maker AV, Carr R. PMID: 26139482.
      View in: PubMed   Mentions:
    51. Symptomatic Massive Splenomegaly in Persistent Polyclonal B-cell Lymphocytosis Requiring Splenectomy. Open J Clin Med Case Rep. 2015; 1(3). Bhagwandin SB, Weisenberg ES, Ozer H, Maker AV. PMID: 26693179.
      View in: PubMed   Mentions:
    52. Tailoring GIST therapy—biology is still king. JAMA Surg. 2015 Apr; 150(4):306-7. Maker AV. PMID: 25671489.
      View in: PubMed   Mentions:
    53. Essential roles of FoxM1 in Ras-induced liver cancer progression and in cancer cells with stem cell features. J Hepatol. 2015 Aug; 63(2):429-36. Kopanja D, Pandey A, Kiefer M, Wang Z, Chandan N, Carr JR, Franks R, Yu DY, Guzman G, Maker A, Raychaudhuri P. PMID: 25828473.
      View in: PubMed   Mentions: 20     Fields:    Translation:HumansAnimalsCells
    54. Simultaneous Occurrence of Glandular and Neuroendocrine Components in Lymph Node Metastasis of Gastric MANEC. Int J Surg Pathol. 2015 Aug; 23(5):375-6. August C, Maker AV, Weisenberg E. PMID: 25807951.
      View in: PubMed   Mentions:
    55. Closure of Melanoma Defects on the Sole of the Foot Using Glaborous Skin: The End of the Flap? Ann Surg Oncol. 2015 Nov; 22(12):4081-2. Maker AV, Iteld L. PMID: 25749930.
      View in: PubMed   Mentions:
    56. Operative management of portal annular pancreas during pancreaticoduodenectomy. Surgery. 2016 Mar; 159(3):972-4. Pardiwala KH, Maker AV. PMID: 26144878.
      View in: PubMed   Mentions:
    57. Genetic evidence that intratumoral T-cell proliferation and activation are associated with recurrence and survival in patients with resected colorectal liver metastases. Cancer Immunol Res. 2015 Apr; 3(4):380-8. Maker AV, Ito H, Mo Q, Weisenberg E, Qin LX, Turcotte S, Maithel S, Shia J, Blumgart L, Fong Y, Jarnagin WR, DeMatteo RP, D'Angelica MI. PMID: 25600439.
      View in: PubMed   Mentions:
    58. Cyst fluid biomarkers for intraductal papillary mucinous neoplasms of the pancreas: a critical review from the international expert meeting on pancreatic branch-duct-intraductal papillary mucinous neoplasms. J Am Coll Surg. 2015 Feb; 220(2):243-53. Maker AV, Carrara S, Jamieson NB, Pelaez-Luna M, Lennon AM, Dal Molin M, Scarpa A, Frulloni L, Brugge WR. PMID: 25592469.
      View in: PubMed   Mentions:
    59. Appendicitis secondary to metastatic melanoma: review of the National Institutes of Health experience. JAMA Surg. 2014 Jul; 149(7):735-8. Kitano M, Maker AV, Lanier BJ, Danforth DN, Kammula US. PMID: 24871401.
      View in: PubMed   Mentions:
    60. Calcifying fibrous tumor of the small intestine associated with Castleman-like lymphadenopathy. J Gastrointest Surg. 2014 Jun; 18(6):1205-8. Valladolid G, Weisenberg E, Sundaresan R, Maker AV. PMID: 24452381.
      View in: PubMed   Mentions:
    61. Dedifferentiated gastrointestinal stromal tumor arising de novo from the small intestine. Pathol Res Pract. 2014 Apr; 210(4):264-6. Choi JJ, Sinada-Bottros L, Maker AV, Weisenberg E. PMID: 24484970.
      View in: PubMed   Mentions:
    62. IG20/MADD plays a critical role in glucose-induced insulin secretion. Diabetes. 2014 May; 63(5):1612-23. Li LC, Wang Y, Carr R, Haddad CS, Li Z, Qian L, Oberholzer J, Maker AV, Wang Q, Prabhakar BS. PMID: 24379354.
      View in: PubMed   Mentions:
    63. Gene expression profiles accurately predict outcome following liver resection in patients with metastatic colorectal cancer. PLoS One. 2013; 8(12):e81680. Ito H, Mo Q, Qin LX, Viale A, Maithel SK, Maker AV, Shia J, Kingham P, Allen P, DeMatteo RP, Fong Y, Jarnagin WR, D'Angelica M. PMID: 24339954.
      View in: PubMed   Mentions:
    64. Benign adrenal hemangiomas may mimic metastases on PET. Clin Nucl Med. 2013 Nov; 38(11):888-90. Calata JF, Sukerkar AN, August CZ, Maker AV. PMID: 24089061.
      View in: PubMed   Mentions:
    65. Management of patients with abdominal malignancy after remote jejunoileal bypass: surgical considerations decades later. J Am Coll Surg. 2013 Nov; 217(5):929-39. Kaminski JP, Maker VK, Maker AV. PMID: 24021299.
      View in: PubMed   Mentions:
    66. A technique for laparoendoscopic resection of posterior fundic gastric GISTs without need for a gastrotomy. Ann Surg Oncol. 2013 Dec; 20(13):4238. Maker AV. PMID: 23943037.
      View in: PubMed   Mentions:
    67. Survival after resection of cutaneous adnexal carcinomas with eccrine differentiation: risk factors and trends in outcomes. J Surg Oncol. 2013 Jul; 108(1):57-62. Avraham JB, Villines D, Maker VK, August C, Maker AV. PMID: 23677677.
      View in: PubMed   Mentions:
    68. Shedding LIGHT (TNFSF14) on the tumor microenvironment of colorectal cancer liver metastases. J Transl Med. 2013 Mar 20; 11:70. Qin JZ, Upadhyay V, Prabhakar B, Maker AV. PMID: 23514280.
      View in: PubMed   Mentions:
    69. MADD knock-down enhances doxorubicin and TRAIL induced apoptosis in breast cancer cells. PLoS One. 2013; 8(2):e56817. Turner A, Li LC, Pilli T, Qian L, Wiley EL, Setty S, Christov K, Ganesh L, Maker AV, Li P, Kanteti P, Das Gupta TK, Prabhakar BS. PMID: 23457619.
      View in: PubMed   Mentions:
    70. Primary hepatic lymphoma presenting as an isolated solitary hepatic cyst. J Clin Oncol. 2013 Jan 10; 31(2):e21-3. Valladolid G, Adams LL, Weisenberg E, Maker VK, Maker AV. PMID: 23169506.
      View in: PubMed   Mentions:
    71. Can we predict which residents are going to pass/fail the oral boards? J Surg Educ. 2012 Nov-Dec; 69(6):705-13. Maker VK, Zahedi MM, Villines D, Maker AV. PMID: 23111034.
      View in: PubMed   Mentions:
    72. Regulatory T cell infiltration predicts outcome following resection of colorectal cancer liver metastases. Ann Surg Oncol. 2013 Mar; 20(3):946-55. Katz SC, Bamboat ZM, Maker AV, Shia J, Pillarisetty VG, Yopp AC, Hedvat CV, Gonen M, Jarnagin WR, Fong Y, D'Angelica MI, DeMatteo RP. PMID: 23010736.
      View in: PubMed   Mentions:
    73. Malignant masquerade of xanthogranulomatous cholecystitis on intraoperative ultrasound of the liver. J Surg Oncol. 2012 Sep 15; 106(4):525-6. Maker AV, Maker VK. PMID: 22410841.
      View in: PubMed   Mentions:
    74. Video: totally laparoscopic left lateral segmentectomy for hepatic malignancies: a modified technique. J Gastrointest Surg. 2011 Sep; 15(9):1650. Maker AV, Jamal W, Gayet B. PMID: 21630104.
      View in: PubMed   Mentions:
    75. Is port site resection necessary in the surgical management of gallbladder cancer? Ann Surg Oncol. 2012 Feb; 19(2):409-17. Maker AV, Butte JM, Oxenberg J, Kuk D, Gonen M, Fong Y, Dematteo RP, D'Angelica MI, Allen PJ, Jarnagin WR. PMID: 21698501.
      View in: PubMed   Mentions:
    76. Knockdown of MADD and c-FLIP overcomes resistance to TRAIL-induced apoptosis in ovarian cancer cells. Am J Obstet Gynecol. 2011 Oct; 205(4):362.e12-25. Li LC, Jayaram S, Ganesh L, Qian L, Rotmensch J, Maker AV, Prabhakar BS. PMID: 21855847.
      View in: PubMed   Mentions:
    77. Cyst fluid interleukin-1beta (IL1beta) levels predict the risk of carcinoma in intraductal papillary mucinous neoplasms of the pancreas. Clin Cancer Res. 2011 Mar 15; 17(6):1502-8. Maker AV, Katabi N, Qin LX, Klimstra DS, Schattner M, Brennan MF, Jarnagin WR, Allen PJ. PMID: 21266527.
      View in: PubMed   Mentions:
    78. Pancreatic cyst fluid and serum mucin levels predict dysplasia in intraductal papillary mucinous neoplasms of the pancreas. Ann Surg Oncol. 2011 Jan; 18(1):199-206. Maker AV, Katabi N, Gonen M, DeMatteo RP, D'Angelica MI, Fong Y, Jarnagin WR, Brennan MF, Allen PJ. PMID: 20717734.
      View in: PubMed   Mentions:
    79. Randomized clinical trials in pancreatic adenocarcinoma. Surg Oncol Clin N Am. 2010 Jan; 19(1):115-50. Rudloff U, Maker AV, Brennan MF, Allen PJ. PMID: 19914563.
      View in: PubMed   Mentions:
    80. Novel presentation of a familial pancreatic cancer syndrome. J Gastrointest Surg. 2009 Jun; 13(6):1151-4. Maker AV, Warth JA, Zinner MJ. PMID: 19089513.
      View in: PubMed   Mentions:
    81. Cytology from pancreatic cysts has marginal utility in surgical decision-making. Ann Surg Oncol. 2008 Nov; 15(11):3187-92. Maker AV, Lee LS, Raut CP, Clancy TE, Swanson RS. PMID: 18766406.
      View in: PubMed   Mentions:
    82. Intrapatient dose escalation of anti-CTLA-4 antibody in patients with metastatic melanoma. J Immunother. 2006 Jul-Aug; 29(4):455-63. Maker AV, Yang JC, Sherry RM, Topalian SL, Kammula US, Royal RE, Hughes M, Yellin MJ, Haworth LR, Levy C, Allen T, Mavroukakis SA, Attia P, Rosenberg SA. PMID: 16799341.
      View in: PubMed   Mentions:
    83. Selective elimination of human regulatory T lymphocytes in vitro with the recombinant immunotoxin LMB-2. J Immunother. 2006 Mar-Apr; 29(2):208-14. Attia P, Powell DJ, Maker AV, Kreitman RJ, Pastan I, Rosenberg SA. PMID: 16531821.
      View in: PubMed   Mentions:
    84. Analysis of the cellular mechanism of antitumor responses and autoimmunity in patients treated with CTLA-4 blockade. J Immunol. 2005 Dec 01; 175(11):7746-54. Maker AV, Attia P, Rosenberg SA. PMID: 16301685.
      View in: PubMed   Mentions:
    85. Inability of a fusion protein of IL-2 and diphtheria toxin (Denileukin Diftitox, DAB389IL-2, ONTAK) to eliminate regulatory T lymphocytes in patients with melanoma. J Immunother. 2005 Nov-Dec; 28(6):582-92. Attia P, Maker AV, Haworth LR, Rogers-Freezer L, Rosenberg SA. PMID: 16224276.
      View in: PubMed   Mentions:
    86. Images in cardiothoracic surgery. Active malignant pleural effusion captured through the thoracoscope. Ann Thorac Surg. 2005 Nov; 80(5):1941. Maker AV, Nguyen DM. PMID: 16242497.
      View in: PubMed   Mentions:
    87. Tumor regression and autoimmunity in patients treated with cytotoxic T lymphocyte-associated antigen 4 blockade and interleukin 2: a phase I/II study. Ann Surg Oncol. 2005 Dec; 12(12):1005-16. Maker AV, Phan GQ, Attia P, Yang JC, Sherry RM, Topalian SL, Kammula US, Royal RE, Haworth LR, Levy C, Kleiner D, Mavroukakis SA, Yellin M, Rosenberg SA. PMID: 16283570.
      View in: PubMed   Mentions:
    88. Loss of S100 antigenicity in metastatic melanoma. Hum Pathol. 2005 Sep; 36(9):1016-9. Aisner DL, Maker A, Rosenberg SA, Berman DM. PMID: 16153466.
      View in: PubMed   Mentions:
    89. Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4. J Clin Oncol. 2005 Sep 01; 23(25):6043-53. Attia P, Phan GQ, Maker AV, Robinson MR, Quezado MM, Yang JC, Sherry RM, Topalian SL, Kammula US, Royal RE, Restifo NP, Haworth LR, Levy C, Mavroukakis SA, Nichol G, Yellin MJ, Rosenberg SA. PMID: 16087944.
      View in: PubMed   Mentions: 263     Fields:    Translation:HumansCTClinical Trials
    90. Rapid acute amiodarone-induced hepatotoxicity in a burn patient. J Burn Care Rehabil. 2005 Jul-Aug; 26(4):341-3. Maker AV, Orgill DP. PMID: 16006841.
      View in: PubMed   Mentions:
    91. Insulin receptor (IR) and glucose transporter 2 (GLUT2) proteins form a complex on the rat hepatocyte membrane. Cell Physiol Biochem. 2005; 15(1-4):51-8. Eisenberg ML, Maker AV, Slezak LA, Nathan JD, Sritharan KC, Jena BP, Geibel JP, Andersen DK. PMID: 15665515.
      View in: PubMed   Mentions:
    Ajay's Networks
    Concepts (425)
    Derived automatically from this person's publications.
    _
    Co-Authors (4)
    People in Profiles who have published with this person.
    _
    Similar People (60)
    People who share similar concepts with this person.
    _
    Same Department
    Search Department
    _